BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Modern surgery for gastric cancer--Japanese perspective. Scand J Surg 2006;95:232-5. [PMID: 17249270 DOI: 10.1177/145749690609500404] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Morgagni P, Tringali D, La Barba G, Vittimberga G, Ercolani G. Historical assumptions of lymphadenectomy. Transl Gastroenterol Hepatol 2016;1:90. [PMID: 28138655 DOI: 10.21037/tgh.2016.11.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Ishigami S, Arigami T, Uchikado Y, Setoyama T, Kita Y, Sasaki K, Okumura H, Kurahara H, Kijima Y, Harada A. IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol. 2013;30:472. [PMID: 23479179 DOI: 10.1007/s12032-013-0472-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
3 Foo M, Leong T. Adjuvant therapy for gastric cancer: Current and future directions. World J Gastroenterol 2014; 20(38): 13718-13727 [PMID: 25320509 DOI: 10.3748/wjg.v20.i38.13718] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
4 Takeuchi H, Kitagawa Y. Is lymphadenectomy a predictor or savior for patients with gastric cancer? Ann Surg Oncol. 2010;17:1257-1258. [PMID: 20140527 DOI: 10.1245/s10434-010-0942-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
5 Marano L, Petrillo M, Pezzella M, Patriti A, Braccio B, Esposito G, Grassia M, Romano A, Torelli F, De Luca R, Fabozzi A, Falco G, Di Martino N. Applicability of the Proposed Japanese Model for the Classification of Gastric Cancer Location: The "PROTRADIST" Retrospective Study. J Invest Surg 2017;30:210-6. [PMID: 27690693 DOI: 10.1080/08941939.2016.1230248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Xie D, Osaiweran H, Liu L, Wang X, Yu C, Tong Y, Hu J, Gong J. Mesogastrium: a fifth route of metastasis in gastric cancer? Med Hypotheses. 2013;80:498-500. [PMID: 23403142 DOI: 10.1016/j.mehy.2012.12.020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
7 Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, Setoyama T, Arima H, Sasaki K, Kitazono M. Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother. 2010;59:389-395. [PMID: 19760221 DOI: 10.1007/s00262-009-0758-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
8 Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, Solej M, Degiuli M. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol 2018; 24(2): 274-289 [PMID: 29375213 DOI: 10.3748/wjg.v24.i2.274] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
9 Kakeji Y, Morita M, Maehara Y. Strategies for treating liver metastasis from gastric cancer. Surg Today. 2010;40:287-294. [PMID: 20339981 DOI: 10.1007/s00595-009-4152-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
10 Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013; 19(21): 3309-3315 [PMID: 23745033 DOI: 10.3748/wjg.v19.i21.3309] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
11 Sue-Ling H. Radical D2 gastrectomy for cancer. The case of D2 resections. Ann R Coll Surg Engl 2007;89:672-4. [PMID: 17959003 DOI: 10.1308/003588407X209518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
12 Verlato G, Giacopuzzi S, Bencivenga M, Morgagni P, Manzoni GD. Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer. World J Gastroenterol 2014; 20(36): 12883-12891 [PMID: 25278685 DOI: 10.3748/wjg.v20.i36.12883] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
13 Vadthya G, Ramakrishnaiah VPN, Krishnamachari S. Short-Term Outcome in Patients Undergoing Gastrectomy with D2 Lymphadenectomy for Carcinoma Stomach. Indian J Surg Oncol 2017;8:304-11. [DOI: 10.1007/s13193-017-0620-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Degiuli M, De Manzoni G, Di Leo A, D’Ugo D, Galasso E, Marrelli D, Petrioli R, Polom K, Roviello F, Santullo F, Morino M. Gastric cancer: Current status of lymph node dissection. World J Gastroenterol 2016; 22(10): 2875-2893 [PMID: 26973384 DOI: 10.3748/wjg.v22.i10.2875] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
15 Kurokawa Y, Sasako M, Sano T, Shibata T, Ito S, Nashimoto A, Kurita A, Kinoshita T; Japan Clinical Oncology Group. Functional outcomes after extended surgery for gastric cancer. Br J Surg 2011;98:239-45. [PMID: 21104822 DOI: 10.1002/bjs.7297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
16 Zheng B, Ma B, Yang K, Mi D. Meta-analysis of randomized controlled trials comparing D2 and D4 lymphadenectomy for gastric cancer. Eur Surg 2011;43:255-61. [DOI: 10.1007/s10353-011-0614-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Mori S, Sawada T, Hamada K, Kita J, Shimoda M, Tagaya N, Kubota K. Gastrectomy for patients with gastric cancer and non-uremic renal failure. World J Gastroenterol 2007; 13(34): 4589-4592 [PMID: 17729411 DOI: 10.3748/wjg.v13.i34.4589] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
18 Kim IH, Park SS, Lee CM, Kim MC, Kwon IK, Min JS, Kim HI, Lee HH, Lee SI, Chae H. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study. Ann Surg Oncol. 2018;25:1176-1183. [PMID: 29450755 DOI: 10.1245/s10434-018-6375-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
19 Tanizawa Y, Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer. 2010;13:137-148. [PMID: 20820982 DOI: 10.1007/s10120-010-0560-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]